Characteristics of study subjects and their lesions
| Lesion outcome | ||
|---|---|---|
| Characteristic | Cancer (in situ) (case subjects) | Cancer free (control subjects) |
| Subjects, n | 12 | 24 |
| Gender | ||
| Male | 10 | 19 |
| Female | 2 | 5 |
| Categorised baseline histology* | ||
| LGD | 3 | 11 |
| HGD | 7 | 10 |
| Indeterminate | 2 | 3 |
| Age at baseline (years) | ||
| Median | 67 | 66 |
| Range | 62–81 | 46–75 |
| Mean±SD | 68±5 | 66±6 |
| Smoking status | ||
| Current | 6 | 11 |
| Former | 6 | 13 |
| Number of pack-years | ||
| Median | 40† | 42 |
| Range | 30–51† | 23–120 |
| COPD status | ||
| Yes | 9 | 17 |
| No | 3 | 6 |
| Unknown | – | 1 |
| COPD staging | ||
| GOLD I—II | 6 | 9 |
| GOLD III—IV | 3 | 8 |
| History of ENT/lung cancer | ||
| Yes | 10 | 14 |
| No | 2 | 10 |
| AFB follow-up time (months) | ||
| Median | 11 | 28‡ |
| Range | 4–24 | 10–80‡ |
| Overall follow-up time (months) | ||
| Median | 32 | 78 |
| Range | 8–118 | 21–142 |
*Lesions were classified into three categories: LGD, HGD and indeterminate on the basis of the highest histomorphological abnormality scored on H&E-stained FFPE and frozen sections (see online supplementary table 1 for detailed information per lesion).
†Number of pack-years is missing for one subject.
‡AFB follow-up is missing for three subjects.
AFB, autofluorescence bronchoscopy; ENT, ear–nose–throat; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HGD, high-grade disease; indeterminate, indefinite for histological grade; LGD, low-grade disease.